- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06393504
Database Study to Provide Information on Pregnancy and Infant Outcomes Among Women Exposed to QUVIVIQ (Daridorexant)
Healthcare Claims Database Study to Provide Safety Information on Maternal, Fetal and Infant Outcomes Among Women Exposed to QUVIVIQ (Daridorexant) During Pregnancy
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a longitudinal observational cohort study using an electronic database of healthcare claims data. Safety information will be retrospectively collected from the database and pre-specified diagnostic codes will be used to identify pregnancy and infant outcomes. The study will include two phases, a patient accrual phase (Phase 1) and an analysis phase (Phase 2).
Descriptive statistics will be conducted to characterize the patient population and to support the interpretation of comparative analyses. Comparative analyses will be performed to estimate the effect of QUVIVIQ exposure during pregnancy on the study outcomes. Approximately 419 mother-infant pairs with exposure to QUVIVIQ and 1676 mother-infant pairs with exposure to non-orexin receptor antagonist insomnia medication are expected with a 1:4 ratio of exposed:active comparator patients.
Analysis of the prevalence of each specific pregnancy or infant outcome will comprise: (1) a comparison between women with insomnia exposed to QUVIVIQ during or shortly prior to pregnancy (QUVIVIQ-exposed group) and women with insomnia exposed to any non-orexin receptor antagonist insomnia medication during or shortly prior to pregnancy (active comparator group); (2) a comparison between women with insomnia exposed to QUVIVIQ during or shortly prior to pregnancy (QUVIVIQ-exposed group) and women with insomnia unexposed to any insomnia medication during or shortly prior to pregnancy (unexposed comparator group).
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Locations
-
-
Delaware
-
Wilmington, Delaware, United States, 19801
- Carelon Research
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
- Evidence of a singleton end of pregnancy event during the intake period.
- ≥ 1 insomnia diagnosis during the period which begins 12 months prior to the date of conception and ends at the end of pregnancy.
- Date of conception ≥ 42 weeks before the end of the intake period.
- Age 15 to 50 years at the date of conception.
- Continuous medical and pharmacy insurance coverage during the period which begins 6 months prior to the date of conception and ends at the end of pregnancy.
- No dispensing of known or suspected teratogenic medications during the period which begins 5 half lives of that medication prior to the date of conception and ends at the end of pregnancy.
- No exposure to other orexin receptor antagonists during the exposure period, i.e., suvorexant, lemborexant, and any orexin receptor antagonists newly approved during the intake period.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
QUVIVIQ-exposed group
Pregnant women with insomnia exposed to QUVIVIQ during pregnancy or within 5 half-lives prior to date of conception.
|
Daridorexant received during or shortly prior to pregnancy.
Other Names:
|
Active comparator group
Pregnant women with insomnia exposed to non-orexin receptor antagonist insomnia medications during pregnancy or within 5 half-lives of the respective insomnia medication prior to date of conception.
|
Non-orexin receptor antagonist insomnia medication received during or shortly prior to pregnancy.
|
Unexposed comparator group
Pregnant women with insomnia unexposed to insomnia medications during pregnancy and within 5 half-lives of any insomnia medication taken prior to date of conception.
|
No insomnia medication received during or shortly prior to pregnancy.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Prevalence of major congenital malformations (MCMs)
Time Frame: From May 2022 to April 2028 (6 years)
|
MCMs will be identified as pre-specified diagnostic codes for malformations included in the National Birth Defects Prevention Network's birth defects descriptions (identified through maternal and infant claims). MCMs with etiologies presumed not to be associated with drug exposure, such as chromosomal abnormalities, genetic syndromes, prematurity-related defects, and positional effects, will be excluded from the definition of MCMs. |
From May 2022 to April 2028 (6 years)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Prevalence of spontaneous abortions (SABs)
Time Frame: From May 2022 to April 2028 (6 years)
|
An SAB is defined as the loss of an embryo before 20 gestational weeks (identified through maternal claims).
|
From May 2022 to April 2028 (6 years)
|
Prevalence of stillbirths (SBs)
Time Frame: From May 2022 to April 2028 (6 years)
|
An SB is defined as the loss of a fetus at or after 20 gestational weeks (identified through maternal claims).
|
From May 2022 to April 2028 (6 years)
|
Prevalence of small for gestational age infants (SGAs)
Time Frame: From May 2022 to April 2028 (6 years)
|
SGA is defined as birth weight less than or equal to the tenth percentile for gestational age (identified through maternal and infant claims).
|
From May 2022 to April 2028 (6 years)
|
Prevalence of preterm births (PTBs)
Time Frame: From May 2022 to April 2028 (6 years)
|
PTB is defined as a live birth before 37 gestational weeks (identified through maternal and infant claims).
|
From May 2022 to April 2028 (6 years)
|
Prevalence of induced abortions (IABs)
Time Frame: From May 2022 to April 2028 (6 years)
|
An IAB is defined as the elective termination of the pregnancy (identified through maternal claims).
|
From May 2022 to April 2028 (6 years)
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Director: Clinical Trials Study Director, Idorsia Pharmaceuticals Ltd.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- ID-078A404
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Insomnia Disorder
-
Bod AustraliaWoolcock Institute of Medical ResearchCompletedInsomnia | Sleep Disturbance | Insomnia Type; Sleep Disorder | Insomnia, Transient | Insomnia Due to Anxiety and Fear | Insomnia Due to Other Mental DisorderAustralia
-
Diakonhjemmet HospitalCompletedSleep Disorder | Insomnia | Sleep Initiation and Maintenance Disorders | Sleep Disturbance | Mental Illness | Depression, Anxiety | Insomnia Chronic | Psychological Disorder | Insomnia Due to Mental Disorder | Insomnia, PsychophysiologicalNorway
-
Federal University of Minas GeraisHarvard Medical School (HMS and HSDM)Active, not recruitingDepressive Disorder | Quality of Life | Sleep Disorder | Anxiety Disorders | Insomnia | Spirituality | Stress Disorder | Insomnia Chronic | Insomnia Disorder | Complementary TherapyBrazil
-
Oberwaid AGUniversity of Zurich; University of Basel; Institute for Exercise and Health...CompletedDepression | Sleep Disorder | Insomnia | Sleep Initiation and Maintenance Disorders | Sleep | Sleep Disturbance | Sleep Fragmentation | Insomnia Due to Other Mental Disorder | Insomnia, Psychophysiological | Insomnia Related to Another Mental ConditionSwitzerland
-
Christin LangDepartment of Sport, Exercise, and Health, University of Basel; University... and other collaboratorsNot yet recruitingInsomnia | Mental Disorder in Adolescence | Delayed Sleep-Wake Phase DisorderSwitzerland
-
National Institute of Mental Health, DhakaSun Pharmaceutical Industries LimitedCompletedMajor Depressive Disorder With InsomniaBangladesh
-
National Taiwan University HospitalNational Science Council, TaiwanUnknownPrimary Insomnia | Depressive Disorders With InsomniaTaiwan
-
University of California, San FranciscoCompleted
-
Laval UniversityCanadian Institutes of Health Research (CIHR)Recruiting
-
University of PennsylvaniaCompletedInsomnia DisorderUnited States
Clinical Trials on Daridorexant
-
Idorsia Pharmaceuticals Ltd.RecruitingInsomniaSpain, United States, Belgium, Germany, Bulgaria
-
Idorsia Pharmaceuticals Ltd.CompletedInsomnia DisorderUnited States, Germany, Canada, Denmark, Poland, Spain, Switzerland, Belgium, Bulgaria, Finland, France, Hungary, Korea, Republic of, Sweden
-
Idorsia Pharmaceuticals Ltd.Completed
-
Idorsia Pharmaceuticals Ltd.Completed
-
Jiangsu Simcere Pharmaceutical Co., Ltd.Recruiting
-
Idorsia Pharmaceuticals Ltd.Completed
-
Idorsia Pharmaceuticals Ltd.CompletedInsomnia DisorderUnited States, Germany, Australia, Canada, Denmark, Italy, Poland, Serbia, Spain, Switzerland
-
Jiangsu Simcere Pharmaceutical Co., Ltd.Completed
-
Idorsia Pharmaceuticals Ltd.Active, not recruitingNocturia | Insomnia DisorderSpain, United States, Germany
-
Idorsia Pharmaceuticals Ltd.CompletedInsomnia DisorderUnited States, Korea, Republic of, Germany, Belgium, Bulgaria, Canada, Czechia, Finland, France, Hungary, Sweden